SCHEMBL5742979

SCHEMBL5742979

O=C(O)C1CCCN1C(=O)CCc1c[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.65
KMT2A Q03164 4/20 0.62
MAPK1 P28482 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MC5R P33032 2/20 0.61
MC3R P41968 1/20 0.61
MC1R Q01726 1/20 0.61
ALDH1A1 P00352 4/20 0.58
LMNA P02545 4/20 0.58
GLA P06280 1/20 0.57
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
RECQL P46063 1/20 0.53
MEN1 O00255 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
BCHE P06276 1/20 0.51
ACHE P22303 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742971 1.00 CYP2C19 (0.65) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL26421741 0.90 MAPK1 (0.61) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL13837136 0.90 CYP2C19 (0.69) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL12480383 0.90 CYP2C19 (0.69) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL26417454 0.87 MAPK1 (0.58) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL26426535 0.85 MAPK1 (0.59) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL15245360 0.84 KMT2A (0.62) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL11218785 0.83 ADAM17 (0.56) CYP2C19KMT2AMAPK1L3MBTL1ALDH1A1
SCHEMBL29206532 0.83 MAPK1 (0.54) CYP2C19KMT2AMAPK1L3MBTL1MC5R
SCHEMBL5546470 0.83 ACE (0.57) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US claimed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US claimed
EP-1244621-B1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS HOFFMANN LA ROCHE (CH) 2006-09-13 EP disclosed
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US disclosed
EP-1244621-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-10-02 EP disclosed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US disclosed
WO-2001047886-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K CTSK, CTSH, CTSS CYP2C19 2377/4885KMT2A 4729/4885MAPK1 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.